Basilea Pharmaceutica AG (BSLN.S)

BSLN.S on Swiss Exchange

97.55CHF
11 Jul 2014
Price Change (% chg)

CHF1.05 (+1.09%)
Prev Close
CHF96.50
Open
CHF97.00
Day's High
CHF98.10
Day's Low
CHF96.70
Volume
46,953
Avg. Vol
106,073
52-wk High
CHF129.80
52-wk Low
CHF66.30

BSLN.S

Chart for BSLN.S

About

Basilea Pharmaceutica AG is a Switzerland-based company engaged in the research, development and commercialization of pharmaceutical products. The Company focuses on pharmaceutical products in the therapeutic areas of bacterial infections, fungal infections and oncology. The Company has a range of drugs to treat drug-resistant... (more)

Overall

Beta: 2.12
Market Cap (Mil.): CHF1,019.53
Shares Outstanding (Mil.): 10.45
Dividend: --
Yield (%): --

Financials

  BSLN.S Industry Sector
P/E (TTM): -- 102.68 35.77
EPS (TTM): -3.40 -- --
ROI: -11.87 -0.70 18.27
ROE: -37.44 -1.57 19.16
Search Stocks

UPDATE 1-Basilea shares fall on setback for pneumonia drug in US

ZURICH, June 25 - Shares in Swiss biotech company Basilea fell by as much as 11.5 percent in early trading on Wednesday following a setback to its efforts to gain U.S. approval for its ceftobiprole treatment for pneumonia.

25 Jun 2014

Basilea shares fall after setback for pneumonia treatment in US

ZURICH, June 25 - Shares in Swiss biotech company Basilea fell 8 percent in early trading on Wednesday following a setback to its efforts to gain U.S. approval for its ceftobiprole treatment for pneumonia.

25 Jun 2014

BRIEF-Basilea Pharmaceutica gives update on ceftobiprole's U.S. regulatory status

June 25 - Basilea Pharmaceutica AG : * Says FDA confirmed that a potential regulatory approval of ceftobiprole in

25 Jun 2014

Basilea starts early-stage study with Gram-negative antibiotic

ZURICH, June 12 - Swiss biotech company Basilea said it had started an early-stage clinical study of an antibiotic to treat infections with multi-drug resistant Gram-negative bacteria in combination with another drug.

12 Jun 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters StreetEvents
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks